Emergent BioSolutions/$EBS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Ticker
$EBS
Sector
Primary listing
NYSE
Industry
Biotechnology
Headquarters
Employees
900
ISIN
US29089Q1058
Website
EBS Metrics
BasicAdvanced
$398M
-
-$2.46
2.09
-
Price and volume
Market cap
$398M
Beta
2.09
52-week high
$15.10
52-week low
$4.02
Average daily volume
1.3M
Financial strength
Current ratio
6.316
Quick ratio
3.153
Long term debt to equity
120.445
Total debt to equity
120.445
Interest coverage (TTM)
-0.69%
Profitability
EBITDA (TTM)
61.8
Gross margin (TTM)
36.60%
Net profit margin (TTM)
-13.63%
Operating margin (TTM)
-4.36%
Effective tax rate (TTM)
-111.24%
Revenue per employee (TTM)
$1,070,000
Management effectiveness
Return on assets (TTM)
-1.61%
Return on equity (TTM)
-21.63%
Valuation
Price to revenue (TTM)
0.407
Price to book
0.72
Price to tangible book (TTM)
5.92
Price to free cash flow (TTM)
3.155
Free cash flow yield (TTM)
31.69%
Free cash flow per share (TTM)
232.31%
Growth
Revenue change (TTM)
-18.56%
Earnings per share change (TTM)
-77.52%
3-year revenue growth (CAGR)
-18.10%
10-year revenue growth (CAGR)
7.70%
3-year earnings per share growth (CAGR)
-6.09%
10-year earnings per share growth (CAGR)
11.25%
What the Analysts think about EBS
Analyst ratings (Buy, Hold, Sell) for Emergent BioSolutions stock.
Bulls say / Bears say
Emergent BioSolutions' sale of its Baltimore-Bayview facility to Syngene International for $36.5 million provides a significant cash infusion, enhancing financial flexibility and aligning with the company's strategic transformation plan. (stocktitan.net)
The appointment of Joseph Papa as CEO, known for successful turnaround efforts at major biotech companies, has been positively received by investors, evidenced by a 70% surge in stock price following the announcement. (investorplace.com)
Emergent BioSolutions secured a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) for their Botulism Antitoxin Heptavalent (BAT®), reinforcing the company's role in U.S. biodefense and providing a substantial revenue stream. (stocktitan.net)
Emergent BioSolutions was removed from the S&P SmallCap 600 index due to its declining market capitalization, reflecting challenges in maintaining its market position. (nasdaq.com)
The company's stock price experienced a significant decline following the announcement of CEO Robert Kramer's resignation, indicating potential instability in leadership. (fool.com)
Emergent BioSolutions' stock was downgraded to a 'Hold' rating by StockNews.com, suggesting concerns about the company's future performance and growth prospects. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
EBS Financial Performance
Revenues and expenses
EBS Earnings Performance
Company profitability
EBS News
AllArticlesVideos
![Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2F7%2Fx%2Fl%2Fpress10-3170490.jpg&w=3840&q=75)
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
GlobeNewsWire·2 days ago
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
GlobeNewsWire·1 week ago
![Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fs%2Fg%2Fr%2Fpress2-3149185.jpg&w=3840&q=75)
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Emergent BioSolutions stock?
Emergent BioSolutions (EBS) has a market cap of $398M as of July 10, 2025.
What is the P/E ratio for Emergent BioSolutions stock?
The price to earnings (P/E) ratio for Emergent BioSolutions (EBS) stock is 0 as of July 10, 2025.
Does Emergent BioSolutions stock pay dividends?
No, Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Emergent BioSolutions dividend payment date?
Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders.
What is the beta indicator for Emergent BioSolutions?
Emergent BioSolutions (EBS) has a beta rating of 2.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.